Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Sbidian

Showing results (1-10 of 142) with videos related to

Pageof 15
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|November 25, 2025
Infectious risk with JAKi: What about atopic dermatitis?Lea Hoisnard, Emilie Sbidian
The British Journal of Dermatology|June 30, 2025
Hormonal therapy and psoriasis risk: a new concern for women's health?Sivem Afach, Emilie Sbidian
The Journal of Investigative Dermatology|September 15, 2009
How to validate outcome instruments for pemphigusSylvie Bastuji-Garin, Emilie Sbidian
JAAD Case Reports|March 10, 2021
Response to "New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019"Florence Assan, Emilie Sbidian, Hervé Bachelez
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2021
ReplyEmilie Sbidian, Laëtitia Penso, Antoine Meyer
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data systemQuentin Samaran, Thomas Bettuzzi, Emilie Sbidian
The Journal of Investigative Dermatology|March 30, 2023
First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative DataClarisse Marcombes, Laetitia Penso, Emilie Sbidian
Rheumatology (Oxford, England)|December 3, 2025
Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort studyMounya Abboud, Mahmoud Zureik, Emilie Sbidian
Rheumatology (Oxford, England)|March 25, 2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: ReplyLaura Pina Vegas, Pascal Claudepierre, Emilie Sbidian
The Journal of Investigative Dermatology|December 23, 2022
Placebo Response in Moderate-to-Severe Psoriasis: Prevalence Meta-Analysis of Randomized Controlled TrialsSivem Afach, Laurence Le Cleach, Emilie Sbidian
Pageof 15

Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
Journal of the European Academy of Dermatology and Venereology : JEADV|November 25, 2025
Infectious risk with JAKi: What about atopic dermatitis?Lea Hoisnard, Emilie Sbidian
The British Journal of Dermatology|June 30, 2025
Hormonal therapy and psoriasis risk: a new concern for women's health?Sivem Afach, Emilie Sbidian
The Journal of Investigative Dermatology|September 15, 2009
How to validate outcome instruments for pemphigusSylvie Bastuji-Garin, Emilie Sbidian
JAAD Case Reports|March 10, 2021
Response to "New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019"Florence Assan, Emilie Sbidian, Hervé Bachelez
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2021
ReplyEmilie Sbidian, Laëtitia Penso, Antoine Meyer
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data systemQuentin Samaran, Thomas Bettuzzi, Emilie Sbidian
The Journal of Investigative Dermatology|March 30, 2023
First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative DataClarisse Marcombes, Laetitia Penso, Emilie Sbidian
Rheumatology (Oxford, England)|December 3, 2025
Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort studyMounya Abboud, Mahmoud Zureik, Emilie Sbidian
Rheumatology (Oxford, England)|March 25, 2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: ReplyLaura Pina Vegas, Pascal Claudepierre, Emilie Sbidian
The Journal of Investigative Dermatology|December 23, 2022
Placebo Response in Moderate-to-Severe Psoriasis: Prevalence Meta-Analysis of Randomized Controlled TrialsSivem Afach, Laurence Le Cleach, Emilie Sbidian
Pageof 15